Drug pricing debates: Can we quantify what a life’s worth?
Industry and academia could be drifting when it comes to evaluating appropriate drug pricing. Here are two views - from venture capitalist Dr. John LaMattina and oncologist Dr. Peter Bach.
puretech ventures